2.04
+0.49%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mesoblast
Its shares trade on ASX under the ticker MSB.AX. It has been listed since 16 December 2004. In the fiscal year to 30 June 2026, it reported revenue of $122.9m and a net loss of $58.8m. At that date it held total assets of $773.1m and shareholders' equity of $568.4m.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-12-16. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), REVASCOR for advanced chronic heart failure (CHF) and MPC-06-ID for chronic low back pain due to degenerative disc disease. The firm's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage CHF. The firm has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. The firm is developing MPC-25-Osteo for spinal fusion.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Dec 2004
- Employees
- 83
- Website
- mesoblast.com ↗
Leadership
Pay as last reported
- Mrs. Jane BellNon-Executive Independent Chairman of the BoardA$230,424
- Dr. Silviu ItescuChief Executive Officer, Executive Director, since 2004A$3.0m
- Mr. William BurnsNon-Executive Independent Vice Chairman of the Board, since 2014A$200,974
- Mr. Andrew ChaponnelInterim Chief Financial Officer
- Dr. Fiona SeeSenior Vice President, Head - Translational Research
- Mr. Peter HowardGeneral Counsel, Corporate Executive
- Dr. Eric RoseExecutive Director, Chief Medical Officer, since 2013A$2.3m
- Mr. Justin HorstHead - Manufacturing
- Mr. Michael SchusterPharma Partnering
- Ms. Geraldine StortonHead - Regulatory Affairs and Quality Management
- Mr. Paul HughesJoint Company Secretary
- Ms. Niva SivakumarJoint Company Secretary
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 55
- Environment
- 55
- Social
- 99
- Governance
- 11
- Women in the workforce
- 52%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mesoblast Ltd has a diverse portfolio of cell therapy products in various stages of development.
- The company has a strong intellectual property portfolio, providing a competitive advantage.
- Mesoblast has established partnerships and collaborations with reputable pharmaceutical companies.
Weaknesses
- Mesoblast faces challenges in successfully commercializing its cell therapy products.
- The company relies heavily on the success of its clinical trials, which pose inherent risks.
- There is a dependence on external funding sources to support ongoing research and development.
Opportunities
- The growing demand for innovative cell-based therapies presents significant market opportunities for Mesoblast.
- Expansion into new geographic regions can help Mesoblast tap into underserved markets.
- The increasing prevalence of chronic diseases provides a target patient population for Mesoblast's products.
Threats
- Competition from other companies in the cell therapy space poses a threat to Mesoblast's market share.
- Regulatory constraints and evolving regulations may impact the company's ability to gain necessary approvals for its products.
- Changes in reimbursement policies and healthcare systems could affect the affordability and accessibility of Mesoblast's therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.